The Effect of Methotrexate 1% Topical Gel on Psoriasis

Document Type : Original Article(s)

Authors

1 Associate Professor, Skin Diseases and Leishmaniasis Research Center And Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Professor, Department of Pharmacology and Toxicology, School of Pharmacy, Isfahan University of Medical Sciences, Isfahan Iran

3 Associate Professor, Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran

Abstract

Background: Psoriasis is one of the most important chronic inflammatory skin diseases, which affects about 3% of people all over the world. However, there is still no unique approach available for treatment of this disease, despite several studies which were performed regarding efficacy and safety of various drugs including methotrexate.Methods: This randomized double-blind study recruited 65 patients with documented psoriasis. Patients were randomly divided into two groups to receive a daily dose of topical gel of methotrexate 1% (group A) or placebo gel (group B) for two months. Patients were followed up to four months.Findings: There were 65 patients, 48 male (75.3%) and 17 female (24.7%), with the mean age of 31 ± 15.7 years and the mean disease duration of 5.5 ± 3.3 years. No significant difference was detected between the two groups of patients according to the response scale after four months. Conclusion: The present study showed that the topical gel methotrexate 1%, when prepared on a base of glycerin, is not effective in improvement of the psoriasis lesions and can not be considered as a first line treatment option in this disease.

Keywords

References

  1. Lebwohl M. Psoriasis. Lancet 2003; 361(9364): 1197-204.
  2. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15(1): 16-7.
  3. Morse RM, Perry HO, Hurt RD. Alcoholism and psoriasis. Alcohol Clin Exp Res 1985; 9(5): 396-9.
  4. Swanbeck G, Inerot A, Martinsson T, Wahlstrom J. A population genetic study of psoriasis. Br J Dermatol 1994; 131(1): 32-9.
  5. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312(13): 818-22.
  6. Jeffes EW, III, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Liu G, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995; 104(2): 183-8.
  7. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res 2005; 54(7): 273-80.
  8. Bonish B, Jullien D, Dutronc Y, Huang BB, Modlin R, Spada FM, et al. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J Immunol 2000; 165(7): 4076-85.
  9. Sigmundsdottir H, Gudjonsson JE, Jonsdottir I, Ludviksson BR, Valdimarsson H. The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol 2001; 126(2): 365-9.
  10. Weinstein GD, Goldfaden G, Frost P. Methotrexate. Mechanism of action on DNA synthesis in psoriasis. Arch Dermatol 1971; 104(3): 236-43.
  11. Newburger AE, Weinstein GD, McCullough JL. Biological and biochemical actions of methotrexate in psoriasis. J Invest Dermatol 1978; 70(4): 183-6.
  12. Roenigk HH, Jr., Auerbach R, Maibach H, Weinstein G, Lebwohl M. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 1998; 38(3): 478-85.
  13. Stewart WD, Wallace SM, Runikis JO. Absorption and local action of methotrexate in human and mouse skin. Arch Dermatol 1972; 106(3): 357-61.
  14. McCullough JL, Synder DS, Weinstein GD, Friedland A, Stein B. Factors affecting human percutaneous penetration of methotrexate and its analogues in vitro. J Invest Dermatol 1976; 66(02): 103-7.
  15. Van Scott EJ, Reinertson RP. Morphologic and physiologic effects of chemotherapeutic agents in psoriasis. J Invest Dermatol 1959; 33: 357-69.
  16. Nurse DS. Effect of antimetabolites on epidermal structures. Arch Dermatol 1963; 87: 258-65.
  17. Comaish S. The effect of methotrexate on skin. Br J Dermatol 1969; 81(7): 551-4.
  18. Bjerring P, Beck HI, Zachariae H, Sogaard H. Topical treatment of psoriatic skin with methotrexate cream: a clinical, pharmacokinetic, and histological study. Acta Derm Venereol 1986; 66(6): 515-9.
  19. Fry L, McMinn RM. Topical methotrexate in psoriasis. Arch Dermatol 1967; 96(5): 483-8.
  20. Ravi Kumar BC, Kaur I, Kumar B. Topical methotrexate therapy in palmoplantar psoriasis. Indian J Dermatol Venereol Leprol 1999; 65(6): 270-2.
  21. Syed TA, Hadi SM, Qureshi ZA, Nordstrom CG, Ali SM. Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study. J Cutan Med Surg 2001; 5(4): 299-302.
  22. Lakshmi PK, Devi GS, Bhaskaran S, Sacchidanand S. Niosomal methotrexate gel in the treatment of localized psoriasis: phase I and phase II studies. Indian J Dermatol Venereol Leprol 2007; 73(3): 157-61.
  23. Weinstein GD, McCullough JL, Olsen E. Topical methotrexate therapy for psoriasis. Arch Dermatol 1989; 125(2): 227-30.
  24. Iraji F, Faghihi G, Siadat AH, Enshaieh S, Shahmoradi Z, Joia A, et al. Efficacy of 15% azelaic acid in psoriasis vulgaris: a randomized, controlled clinical trial. J Drugs Dermatol 2010; 9(8): 964-8.
Journal of Isfahan Medical School
Volume 29, Issue 173 - Serial Number 173
November and December 2012
Pages 3087-3092

Files

History

  • Receive Date: 18 March 2012
  • Revise Date: 29 April 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics